Tirzepatide
Tirzepatide 5mg lyophilised powder — the starting dosage for clinical titration protocols. Produced to pharmaceutical-grade standards for clinical weight management and metabolic health applications.
Request a Quote
Pricing available for qualified medical professionals, clinics, and distributors.
Enquire NowDownload MonographView FAQMechanism of Action
Tirzepatide is a dual agonist targeting both GIP and GLP-1 receptors. GIP receptor activation enhances insulin secretion and may potentiate the appetite-suppressing effects of GLP-1 signalling. GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and promotes satiety. The SURMOUNT-1 trial demonstrated mean body weight reductions of up to 22.5% at 72 weeks with tirzepatide.
Read the researchClinical Benefits
- Dual receptor agonist (GIP/GLP-1)
- Supports metabolic health and weight management
- Entry-level dosage for titration
- Pharmaceutical-grade formulation
Specifications
Storage & Handling
- Store lyophilised vials at 2–8°C
- Protect from light
- Reconstituted solution: 2–8°C, use per clinical protocol
For professional medical use only. Not for retail sale to the general public. Pricing available on request for qualified medical institutions and distributors.